68Ga-NODAGA-SNA006: 68Ga-NODAGA-SNA006 PET/CT: after intravenous injection of 0.05 mCi/kg body weight of quality-controlled 68Ga-NODAGA-SNA006, an integrated PET/CT scanner (Biograph mCT; Siemens, Germany) will be applied.
Study summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in subjects with solid tumor or lymphoma.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Participants who were diagnosed with malignant tumors;
2. Patients are between 18 and 80 years of age are between 18 and 80 years of age.
Exclusion Criteria:
1. Participants who were unable or unwilling to provide written informed consent.
2. Participants who were unable to successfully complete the examination and are forced to abort the test in the middle of the test
Primary outcome measure(s)
Incidence of 68Ga-NODAGA-SNA006-emergent Adverse Events — 3 YEAR Through PET/CT, Visual analysis was positive, or the SUVmax was more than the mediastinum
Biodistribution of 68Ga-NODAGA-SNA006 — 3 YEAR Through PET/CT analysis, SUVmax and SUVmean of the organs
Trial sites (1)
Facility
City
Region
Status
The First Hospital of China Medical University
Shenyang
Liaoning
More First Hospital of China Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.